Illustrative certificateNS-2026-06047

Nordicstar Analytical Sciences

Tesamorelin 10 MG

99.696%HPLC purity

Lot: GLZ-26-TESA-1046
Measured content: 10.06 mg
Mass-spec identity: Confirmed
Endotoxin: <1.0 EU/mg
Tested: 23 Sep 2026

View Lab Report

Repair & Recovery

Tesamorelin

Q: What is Tesamorelin?

Tesamorelin, also known as TH9507 or TH-9507, is a 44-amino-acid synthetic analogue of human GHRH/GRF. It contains a trans-3-hexenoyl modification at the N-terminal Tyr1 residue.

Q: How does the molecule relate to native GHRH?

Tesamorelin closely follows the human GRF(1–44) peptide sequence and contains an N-terminal trans-3-hexenoyl modification. This distinguishes its molecular design from native GHRH and from the shorter GHRH(1–29) analogues.

GHRH receptor pharmacology & peptide stability

$79.00USD / vialView COA

A pair saves 10%. A set of three saves 15%.

For laboratory research use only.
Not for human consumption or clinical use.

Compound details

Compound: Tesamorelin
CAS number: 218949-48-5
Molecular formula: C223H352N44O50S
Molecular weight: 5135.85 g/mol
Form: Lyophilized

Quality & documentation

The records shown here are illustrative. Request laboratory-issued documentation for your lot before ordering.

Lot: GLZ-26-TESA-1046
HPLC purity: 99.696%
Measured content: 10.06 mg
Tested: 23 Sep 2026
Report: NS-2026-06047

View the 10 MG certificate

Our quality approach

Shipping & handling

Priority, tracked shipping within the United States, free on orders of $200 or more after savings. Add Priority dispatch at checkout to have your order packed first; Private Clients receive it on every order. Follow the product documentation for laboratory handling requirements.

Shipping information

Explore the research profile

Tesamorelin10 MG · Single

$79.00

01 / The compound

Understand
the starting point.

GHRH receptor pharmacology & peptide stability

Tesamorelin, also known by the development code TH9507, is a 44-amino-acid synthetic analogue of growth hormone-releasing hormone (GHRH/GRF). Its peptide sequence corresponds closely to human GRF(1-44), with a trans-3-hexenoyl modification at the N-terminal Tyr1 residue.

Laboratory research has examined Tesamorelin in relation to GHRH-receptor pharmacology, peptide stability, enzymatic resistance and signaling within the GH/IGF-1 axis. The N-terminal modification is an important structural feature because it was developed to alter stability relative to native GHRH.

02 / Research profile

The pathways.
The possibilities.

Published pharmacology has characterized Tesamorelin as a GHRH analogue with receptor-binding properties comparable to native human GRF. Research has examined the compound within the GHRH signaling pathway and downstream GH/IGF-1 biology.

GHRH / GRF receptor

Human GRF(1-44) sequence

Trans-3-hexenoyl group at Tyr1

GHRH receptor signaling → GH-axis activity → downstream IGF-1 measurements

This pathway summarizes areas evaluated in published research and is not a human-use protocol or therapeutic recommendation.

Research measurements follow different stages of the pathway, from GHRH-receptor interaction to downstream GH-axis activity and IGF-1 measurements. These endpoints describe experimental pharmacology and do not establish equivalence between different tesamorelin formulations.

01 / Research focus

Receptor pharmacology

Published pharmacology characterizes tesamorelin as a GHRH analogue with receptor-binding properties comparable to native human GRF. Experimental measurements relate to receptor interaction and downstream GHRH-axis signaling.

02 / Research focus

Structural stability

The trans-3-hexenoyl group at the N-terminal Tyr1 residue is a defining modification studied in relation to peptide stability and resistance to enzymatic degradation.

Reading the evidence

The cited findings describe the compound in the experimental systems used. Cellular, biochemical and animal results should be interpreted according to their model, methods and endpoints; they do not establish the performance of a GLPZone lot.

03 / Reference data

The details,
in plain sight.

Reference specifications describe a compound. The final lot documentation identifies the material supplied.

Tesamorelin reference specifications
Compound	Tesamorelin
Research area	Repair & Recovery
CAS number	218949-48-5
Molecular formula	C223H352N44O50S
Molecular weight	5135.85 g/mol
Physical form	Lyophilized
Vial options	10 MG · 20 MG
Intended use	Laboratory research only

Variant amounts are nominal catalog quantities. They are not instructions for use.

04 / Quality & documentation

A number needs
its context.

How testing works

01 / Purity

What is in the sample?

HPLC separates components under a defined method. Read the reported percentage alongside the chromatogram, wavelength, integration method, and scope of the test.

02 / Identity

Is it the expected compound?

Mass spectrometry provides molecular-mass evidence. Identity and chromatographic purity answer different questions; one cannot stand in for the other.

03 / Traceability

Does the report match the vial?

Connect the product name, variant, lot identifier, report date, and issuing laboratory. A report is useful only when its sample can be linked to the material being reviewed.

Independent analysis

Every Tesamorelin lot is analyzed by Nordicstar Analytical Sciences for identity, content, and purity by HPLC with LC-MS confirmation. Each certificate carries a report number and verification key that can be checked at nordicstarlabs.com/verify. Research references below describe published science, not a certificate for a vial.

Read a COA with confidence

Tesamorelin lot certificates
Presentation	Lot	HPLC purity	Tested	Certificate
10 MG Current lot	`GLZ-26-TESA-1046`	99.696%	23 Sep 2026	NS-2026-06047
20 MG Current lot	`GLZ-26-TESA-1047`	99.603%	14 Sep 2026	NS-2026-06048
20 MG	`GLZ-26-TESA-753`	99.647%	18 Aug 2026	NS-2026-06167
10 MG	`GLZ-26-TESA-754`	99.571%	16 Aug 2026	NS-2026-06165
10 MG	`GLZ-26-TESA-654`	99.609%	13 Jul 2026	NS-2026-06166
20 MG	`GLZ-26-TESA-653`	99.768%	11 Jul 2026	NS-2026-06168

05 / Storage & handling

Care for
the material.

Tesamorelin is supplied as lyophilized research material. Storage and stability requirements can depend on the specific formulation, packaging and manufacturer-supported stability data.

Product-specific documentation is required to establish a storage temperature, preparation method or solution stability period.

Explore the handling guide

06 / Common questions

A little more
understanding.

What is Tesamorelin?

Tesamorelin, also known as TH9507 or TH-9507, is a 44-amino-acid synthetic analogue of human GHRH/GRF. It contains a trans-3-hexenoyl modification at the N-terminal Tyr1 residue.

How does the molecule relate to native GHRH?

Tesamorelin closely follows the human GRF(1–44) peptide sequence and contains an N-terminal trans-3-hexenoyl modification. This distinguishes its molecular design from native GHRH and from the shorter GHRH(1–29) analogues.

07 / Further reading